Predicting Alzheimer's disease progression using rs-fMRI and a history-aware graph neural network

TL;DR

This study introduces a graph neural network model that uses rs-fMRI data and visit history to predict Alzheimer's disease progression, achieving high accuracy even with irregular visit data.

Contribution

It presents a novel RNN-enhanced GNN model that effectively predicts cognitive decline stages using functional connectivity graphs from rs-fMRI scans.

Findings

Achieved 82.9% overall accuracy in predicting disease progression.

Attained 68.8% accuracy specifically for CN to MCI conversion.

Model remains robust with missing visits and irregular time gaps.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder that affects more than seven million people in the United States alone. AD currently has no cure, but there are ways to potentially slow its progression if caught early enough. In this study, we propose a graph neural network (GNN)-based model for predicting whether a subject will transition to a more severe stage of cognitive impairment at their next clinical visit. We consider three stages of cognitive impairment in order of severity: cognitively normal (CN), mild cognitive impairment (MCI), and AD. We use functional connectivity graphs derived from resting-state functional magnetic resonance imaging (rs-fMRI) scans of 303 subjects, each with a different number of visits. Our GNN-based model incorporates a recurrent neural network (RNN) block, enabling it to process data from the subject's entire visit history. It can also work with irregular time gaps between visits by incorporating visit distance information into our input features. Our model demonstrates robust predictive performance, even with missing visits in the subjects' visit histories. It achieves an accuracy of 82.9%, with an especially impressive accuracy of 68.8% on CN to MCI conversions - a task that poses a substantial challenge in the field. Our results highlight the effectiveness of rs-fMRI in predicting the onset of MCI or AD and, in conjunction with other modalities, could offer a viable method for enabling timely interventions to slow the progression of cognitive impairment.